Cool article. It's related to, but not identical to our product. That paper uses β-lactamase activity as a proxy for antibacterial resistance. Ours, on the other hand, works for pretty much any bacterium; using a fluorescence microscope we count how many bacteria are left alive when exposed to an antibacterial. If there are a lot left alive, then they're probably resistant.
Hey hey,
A friend and I are developing a test for antibacterial resistant infections using fluorescent dyeing that is 10 times faster than existing tests. We want to know what the process is for getting clinical laboratories to adopt our product as a standard test. This information would help us customize our prototype and pitches towards the relevant parties.